Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

Autor: Remy Klaassen, Oliver J. Gurney-Champion, Marie Cecile J.C. Legdeur, Marjolein C. H. Pleunis-van Empel, Hanneke W. M. van Laarhoven, Johanna W. Wilmink, Koen S. van der Lee, Aart J. Nederveen, Esther N. Pijnappel, Dick J. Richel, Nienke P. M. Wassenaar

Publikováno v: Cancers
Volume 13
Issue 19
Cancers, 13(19):4869. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 13, Iss 4869, p 4869 (2021)

Background: Desmoplasia is a central feature of the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC). LDE225 is a pharmacological Hedgehog signaling pathway inhibitor and is thought to specifically target tumor stroma. We investigate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a29658cb32aaf5f68c2443f3da0f5aad